• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

少突胶质细胞瘤:组织学诊断与分级的可重复性及预后价值

Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading.

作者信息

Giannini C, Scheithauer B W, Weaver A L, Burger P C, Kros J M, Mork S, Graeber M B, Bauserman S, Buckner J C, Burton J, Riepe R, Tazelaar H D, Nascimento A G, Crotty T, Keeney G L, Pernicone P, Altermatt H

机构信息

Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62. doi: 10.1093/jnen/60.3.248.

DOI:10.1093/jnen/60.3.248
PMID:11245209
Abstract

Prognostic value of histological grading of oligodendroglial tumors is controversial and interobserver reproducibility in grading of these tumors is unknown. Seven neuropathologists and 6 surgical pathologists experienced in brain tumor-diagnosis assessed 124 oligodendroglial tumors operated at the Mayo Clinic (1960-1990). Among histologic parameters upon which current oligodendroglioma grading systems are based, only high cellularity, presence of mitoses, microcalcifications, endothelial hypertrophy, endothelial proliferation, and necrosis appeared to be reproducible. Reproducible histologic features, based on consensus ratings among neuropathologists (defined as > 60%), were evaluated for the association with cause-specific survival by fitting Cox regression models. By univariate analysis, a significant association with survival was found for age, high cellularity, presence of mitoses, endothelial hypertrophy and proliferation and necrosis. On multivariable analysis with a stepwise variable selection method, only age and presence of endothelial proliferation were found to be independently associated with survival with a discriminatory index of the model of 0.68. Mitotic index was significantly associated with survival based on the grading from each separate neuropathologist, but it was not based on consensus, most likely because this was classified as indeterminate in 54% of cases. Alternatively, "models fit" considering the assessment of single neuropathologists, identified a model based on age and on mitotic index with similar discriminatory indices of 0.69-0.7. Our study found few factors independently associated with cause specific-survival among morphological parameters. These findings are consistent with the present WHO stratification of oligodendrogliomas into low- and high-grade variants.

摘要

少突胶质细胞瘤组织学分级的预后价值存在争议,且这些肿瘤分级的观察者间可重复性尚不清楚。7名神经病理学家和6名有脑肿瘤诊断经验的外科病理学家对梅奥诊所(1960 - 1990年)手术的124例少突胶质细胞瘤进行了评估。在当前少突胶质细胞瘤分级系统所依据的组织学参数中,只有高细胞密度、有丝分裂、微钙化、内皮细胞肥大、内皮细胞增殖和坏死似乎具有可重复性。基于神经病理学家间的共识评分(定义为> 60%)的可重复组织学特征,通过拟合Cox回归模型评估其与特定病因生存率的相关性。单因素分析发现,年龄、高细胞密度、有丝分裂、内皮细胞肥大、增殖和坏死与生存率有显著相关性。采用逐步变量选择法进行多因素分析时,仅发现年龄和内皮细胞增殖与生存率独立相关,模型的判别指数为0.68。根据每位独立神经病理学家的分级,有丝分裂指数与生存率显著相关,但基于共识则不然,很可能是因为在54%的病例中其被归类为不确定。另外,考虑单个神经病理学家评估的“模型拟合”确定了一个基于年龄和有丝分裂指数的模型,其判别指数相似,为0.69 - 0.7。我们的研究发现形态学参数中很少有因素与特定病因生存率独立相关。这些发现与世界卫生组织目前将少突胶质细胞瘤分为低级别和高级别变体的分层一致。

相似文献

1
Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading.少突胶质细胞瘤:组织学诊断与分级的可重复性及预后价值
J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62. doi: 10.1093/jnen/60.3.248.
2
Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.基于组织病理学标准的少突胶质细胞瘤分类是生存的重要预测指标——临床、影像学和病理学长期随访分析。
Clin Neuropathol. 2009 Jan-Feb;28(1):11-20. doi: 10.5414/npp28011.
3
[Grading of astrocytomas and oligodendrogliomas].[星形细胞瘤和少突胶质细胞瘤的分级]
Pathologe. 1998 Jul;19(4):259-68. doi: 10.1007/s002920050282.
4
Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma.
Cancer. 2000 Feb 15;88(4):862-9. doi: 10.1002/(sici)1097-0142(20000215)88:4<862::aid-cncr17>3.0.co;2-g.
5
Prognostic relevance of DNA flow cytometry in oligodendroglioma.DNA 流式细胞术在少突胶质细胞瘤中的预后相关性
Cancer. 1992 Apr 1;69(7):1791-8. doi: 10.1002/1097-0142(19920401)69:7<1791::aid-cncr2820690722>3.0.co;2-z.
6
Mitosis identification in diffuse gliomas: implications for tumor grading.弥漫性胶质瘤中的有丝分裂识别:对肿瘤分级的意义。
Cancer. 1998 Apr 15;82(8):1550-5.
7
Clinicopathologic correlations in the oligodendroglioma.
Cancer. 1987 Apr 1;59(7):1345-52. doi: 10.1002/1097-0142(19870401)59:7<1345::aid-cncr2820590719>3.0.co;2-a.
8
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.坏死在少突胶质细胞瘤分级中的意义:一项对新诊断的高级别胶质瘤的临床病理和遗传学研究
J Clin Oncol. 2006 Dec 1;24(34):5419-26. doi: 10.1200/JCO.2006.08.1497.
9
The prognostic significance of Ki-67 labeling indices for oligodendrogliomas.少突胶质细胞瘤中Ki-67标记指数的预后意义
Neurosurgery. 1997 Oct;41(4):878-84; discussion 884-5. doi: 10.1097/00006123-199710000-00021.
10
Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
Cancer. 1996 Sep 1;78(5):1107-13. doi: 10.1002/(SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5.

引用本文的文献

1
DNA methylation analysis reveals an epigenetic signature distinctive of high-grade oligodendroglioma.DNA甲基化分析揭示了高级别少突胶质细胞瘤独特的表观遗传特征。
Acta Neuropathol. 2025 Aug 23;150(1):21. doi: 10.1007/s00401-025-02926-y.
2
Revisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features.重新审视2021年世界卫生组织分类中少突胶质细胞瘤患者的预后:影像特征的增量价值。
Eur Radiol. 2025 Jul 9. doi: 10.1007/s00330-025-11768-x.
3
1p and/or 19q polysomy is an adverse prognostic factor in oligodendrogliomas, and easy to detect by automated FISH.
1p和/或19q多体性是少突胶质细胞瘤的不良预后因素,且易于通过自动化荧光原位杂交(FISH)检测到。
PLoS One. 2025 May 2;20(5):e0322809. doi: 10.1371/journal.pone.0322809. eCollection 2025.
4
The time has come for an integrated and multiscale grading system for oligodendrogliomas IDH-mutant and 1p/19q co-deleted mixing imaging and histomolecular parameters.为少突胶质细胞瘤(异柠檬酸脱氢酶(IDH)突变型和1p/19q共缺失)整合多尺度分级系统并结合影像学和组织分子参数的时机已经成熟。
Neuro Oncol. 2025 May 15;27(4):1128-1129. doi: 10.1093/neuonc/noaf022.
5
Context aware machine learning techniques for brain tumor classification and detection - A review.用于脑肿瘤分类与检测的上下文感知机器学习技术——综述
Heliyon. 2025 Jan 13;11(2):e41835. doi: 10.1016/j.heliyon.2025.e41835. eCollection 2025 Jan 30.
6
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.伏立西尼在非强化复发性中枢神经系统WHO 3级少突胶质细胞瘤中的扩大应用
Biomedicines. 2025 Jan 15;13(1):201. doi: 10.3390/biomedicines13010201.
7
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.对中枢神经系统WHO 3级异柠檬酸脱氢酶(IDH)突变型和1p/19q共缺失型少突胶质细胞瘤预后因素的重新评估:来自法国POLA队列的经验教训。
Neuro Oncol. 2025 Mar 7;27(3):755-766. doi: 10.1093/neuonc/noae221.
8
Revisiting oligodendroglioma grading in the 2021 WHO classification: calcification and larger contrast-enhancing tumor volume may predict higher oligodendroglioma grade.重新审视 2021 年 WHO 分类中的少突胶质细胞瘤分级:钙化和更大的对比增强肿瘤体积可能预示着更高的少突胶质细胞瘤分级。
Neuroradiology. 2024 Sep;66(9):1527-1535. doi: 10.1007/s00234-024-03430-y. Epub 2024 Jul 17.
9
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?IDH 突变型胶质瘤中肿瘤分级、年龄、强化和切除程度的生物学意义:在 IDH 抑制剂时代,它们应如何影响治疗决策?
Neuro Oncol. 2024 Oct 3;26(10):1805-1822. doi: 10.1093/neuonc/noae107.
10
Diagnostic algorithm for glioma grading using dynamic susceptibility contrast‑enhanced magnetic resonance perfusion and proton magnetic resonance spectroscopy.使用动态磁敏感对比增强磁共振灌注成像和质子磁共振波谱的胶质瘤分级诊断算法
Biomed Rep. 2024 Feb 1;20(3):56. doi: 10.3892/br.2024.1741. eCollection 2024 Mar.